09:07 AM EDT, 10/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Thursday that it has completed recruitment for the first part of its early-stage trial for IMP761, a LAG-3 immunotherapy aimed at treating autoimmune diseases.

The part A, single dose, of the placebo-controlled, double-blind trial reported no safety issues following drug administration, the company said. The trial will now move on to the second part, which involves increasing the dose from 0.03 mg/kg up to 0.90 mg/kg in a cohort of 30 healthy volunteers.

The part B will evaluate safety as well as pharmacokinetics/pharmacodynamics, or PK/PD, Immutep ( IMMP ) said. Results from the safety evaluation are expected by year-end, with PK/PD data anticipated in H1 next year, it said.

Immutep ( IMMP ) shares rose nearly 3% in recent Thursday premarket activity.

Price: 2.0982, Change: +0.06, Percent Change: +2.85